Recent News
Nov 21, 2025 — The U.K. cost‑effectiveness body recommended Amvuttra (vutrisiran) for NHS use in ATTR‑CM, with final guidance expected next month. Oct 7, 2025 — Morgan Stanley raised its price target on the company. Sep 18, 2025 — Alnylam and Moderna reached a settlement in patent litigation related to lipid nanoparticle technology. Nov 4–19, 2025 — Alnylam scheduled and announced investor‑conference presentations and webcasts for November events.
Technical Analysis
ADX at 19.42 indicates no strong directional trend; that limited trend strength suggests price moves likely remain range‑bound versus a sustained breakout supporting valuation changes.
Directional indicators show weakening bullish force: DI+ sits at 19.22 with a peak & reversal, which signals declining bullish pressure; DI‑ reads 16.65 with a dip & reversal, indicating rising bearish pressure. Together these DI moves skew near‑term directional odds toward sellers.
MACD at -1.25 with a peak & reversal denotes bearish momentum despite the MACD currently trading above its signal line (-1.63), which constitutes a recent bullish crossover; the prevailing MACD pattern favors fading upside attempts rather than sustained rallies.
MRO at 15.03 with a peak & reversal shows price currently sits above the WMDST target and implies a potential for downward reversion from current levels.
RSI at 52.28 with a peak & reversal sits near neutral but indicates momentum has peaked and may roll lower, reducing the likelihood of a sustained breakout above short‑term resistance.
Price sits near the 20‑day average ($446.73) and below the 50‑day average ($457.91) while well above the 200‑day average ($348.34); the 20‑day EMA and 12‑day EMA show peak & reversal traits, which aligns with short‑term fading strength. The super trend upper band at $466.06 and the Ichimoku Senkou A at $460.72 act as nearby resistance ceilings.
Volatility measures remain low: 42‑day volatility 2% and 52‑week volatility 3%, and recent daily volume (781,685) sits below 10/50/200‑day averages, indicating thinner participation during recent price moves and higher sensitivity to news‑driven flows.
Fundamental Analysis
Revenue and profitability: Total revenue $1,249,026,000 with YoY revenue growth reported as 61.44% and a quarterly change listed as 103.38%; the dataset also lists revenue growth YoY at -355.11%, which reflects differing period comparisons. Gross margin stands at 83.98% and operating margin at 29.46%, with EBIT margin of 22.69%, signaling strong product economics relative to peers: the industry peer mean EBIT margin equals -124.97% and the industry peer median equals 36.65% (industry peer high 32.71). Operating margin declined QoQ by 15.07% and shows a YoY contraction of 2.99%, indicating recent margin compression despite high absolute margins.
Earnings and cash flow: GAAP EPS $2.90 versus an estimate of $1.75, producing an EPS surprise of 65.71%. EBIT $283,367,000 and EBITDA $297,170,000 accompanied by net income $251,084,000. Operating cash flow $325,109,000 and free cash flow $312,967,000 yield a free cash flow yield of 0.54%, modestly above the industry peer mean of 0.31%.
Balance sheet and leverage: Cash $1,490,249,000 and cash & short‑term investments $2,724,624,000 provide liquidity support; current ratio 2.54 and quick ratio 2.49 indicate comfortable near‑term coverage. Total debt $1,308,452,000 produces debt‑to‑assets of 26.97% and debt‑to‑equity of 559.42%, which sits well above the industry peer mean debt‑to‑equity of 15.54% and signals materially higher leverage versus typical biotech peers. Debt‑to‑EBITDA stands at 4.40x, implying measurable leverage relative to earnings.
Returns and growth: Return on equity reads 107.35% and return on assets 5.33%; earnings growth registers -668.63% in the provided metric while earnings growth QoQ and YoY show contractions (-113.37% QoQ, -217.46% YoY in the dataset format). Research & development expense totaled $358,814,000, reflecting ongoing pipeline investment. Asset turnover 0.27 and operating leverage 92.73 reflect high fixed cost absorption given product mix and growth.
Valuation: Price multiples sit elevated—P/E 151.99, P/S 46.51, P/B 248.36—and enterprise multiple 190.71. Forward EPS negative (-$0.305) renders forward P/E not meaningful in traditional terms. WMDST values the stock as under‑valued based on the firm’s cash generation, high product margins, and WMDST’s intrinsic framework despite headline multiples that appear stretched.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-09-30 |
| REPORT DATE: | 2025-10-30 |
| NEXT REPORT DATE: | 2026-01-29 |
| CASH FLOW | Begin Period Cash Flow | $ 1.1 B |
| Operating Cash Flow | $ 325.1 M | |
| Capital Expenditures | $ -12.14 M | |
| Change In Working Capital | $ -204.66 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 376.9 M | |
| End Period Cash Flow | $ 1.5 B | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 1.2 B | |
| Forward Revenue | $ -49.99 M | |
| COSTS | ||
| Cost Of Revenue | $ 200.2 M | |
| Depreciation | $ 13.8 M | |
| Depreciation and Amortization | $ 13.8 M | |
| Research and Development | $ 358.8 M | |
| Total Operating Expenses | $ 881.0 M | |
| PROFITABILITY | ||
| Gross Profit | $ 1.0 B | |
| EBITDA | $ 297.2 M | |
| EBIT | $ 283.4 M | |
| Operating Income | $ 368.0 M | |
| Interest Income | $ 28.7 M | |
| Interest Expense | $ 44.4 M | |
| Net Interest Income | $ -15.72 M | |
| Income Before Tax | $ 239.0 M | |
| Tax Provision | $ -12.12 M | |
| Tax Rate | 21.0 % | |
| Net Income | $ 251.1 M | |
| Net Income From Continuing Operations | $ 251.1 M | |
| EARNINGS | ||
| EPS Estimate | $ 1.75 | |
| EPS Actual | $ 2.90 | |
| EPS Difference | $ 1.15 | |
| EPS Surprise | 65.714 % | |
| Forward EPS | $ -0.30 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 4.9 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 233.9 M | |
| Total Current Assets | $ 4.0 B | |
| Cash and Short-Term Investments | $ 2.7 B | |
| Cash | $ 1.5 B | |
| Net Receivables | $ 964.8 M | |
| Inventory | $ 75.4 M | |
| Long-Term Investments | $ 107.1 M | |
| LIABILITIES | ||
| Accounts Payable | $ 117.6 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 1.6 B | |
| Net Debt | — | |
| Total Debt | $ 1.3 B | |
| Total Liabilities | $ 4.6 B | |
| EQUITY | ||
| Total Equity | $ 233.9 M | |
| Retained Earnings | $ -7.16 B | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 1.77 | |
| Shares Outstanding | 131.791 M | |
| Revenue Per-Share | $ 9.48 | |
| VALUATION | Market Capitalization | $ 58.1 B |
| Enterprise Value | $ 56.7 B | |
| Enterprise Multiple | 190.713 | |
| Enterprise Multiple QoQ | -92.442 % | |
| Enterprise Multiple YoY | -128.289 % | |
| Enterprise Multiple IPRWA | ALNY: 190.713 high: 52.77 median: 26.559 mean: 3.817 low: -80.476 |
|
| EV/R | 45.375 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 20.743 | |
| Asset To Liability | 1.051 | |
| Debt To Capital | 0.848 | |
| Debt To Assets | 0.27 | |
| Debt To Assets QoQ | -5.062 % | |
| Debt To Assets YoY | 2591.517 % | |
| Debt To Assets IPRWA | high: 1.045 ALNY: 0.27 mean: 0.211 median: 0.073 low: 0.0 |
|
| Debt To Equity | 5.594 | |
| Debt To Equity QoQ | 8.079 % | |
| Debt To Equity YoY | 329.468 % | |
| Debt To Equity IPRWA | ALNY: 5.594 high: 1.346 mean: 0.155 median: 0.09 low: -0.81 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 248.362 | |
| Price To Book QoQ | 26.804 % | |
| Price To Book YoY | -76.77 % | |
| Price To Book IPRWA | ALNY: 248.362 high: 18.42 mean: 7.014 median: 5.8 low: -8.555 |
|
| Price To Earnings (P/E) | 151.992 | |
| Price To Earnings QoQ | -125.393 % | |
| Price To Earnings YoY | -149.252 % | |
| Price To Earnings IPRWA | ALNY: 151.992 high: 56.753 mean: -3.695 median: -11.857 low: -93.179 |
|
| PE/G Ratio | -0.227 | |
| Price To Sales (P/S) | 46.508 | |
| Price To Sales QoQ | -26.687 % | |
| Price To Sales YoY | -32.651 % | |
| Price To Sales IPRWA | high: 1129.647 mean: 75.828 ALNY: 46.508 median: 21.692 low: 0.808 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | -1353.481 | |
| Forward PE/G | 2.024 | |
| Forward P/S | -1162.052 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | 92.731 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.265 | |
| Asset Turnover Ratio QoQ | 50.505 % | |
| Asset Turnover Ratio YoY | 117.489 % | |
| Asset Turnover Ratio IPRWA | high: 0.438 ALNY: 0.265 median: 0.107 mean: 0.106 low: 0.0 |
|
| Receivables Turnover | 1.631 | |
| Receivables Turnover Ratio QoQ | 3.82 % | |
| Receivables Turnover Ratio YoY | 7.972 % | |
| Receivables Turnover Ratio IPRWA | high: 6.279 ALNY: 1.631 mean: 1.435 median: 1.335 low: 0.009 |
|
| Inventory Turnover | 2.722 | |
| Inventory Turnover Ratio QoQ | 30.682 % | |
| Inventory Turnover Ratio YoY | 153.426 % | |
| Inventory Turnover Ratio IPRWA | ALNY: 2.722 high: 2.635 mean: 0.417 median: 0.301 low: -0.015 |
|
| Days Sales Outstanding (DSO) | 55.957 | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | 32.686 | |
| Cash Conversion Cycle Days QoQ | 82.194 % | |
| Cash Conversion Cycle Days YoY | -53.64 % | |
| Cash Conversion Cycle Days IPRWA | high: 1122.555 mean: 204.336 median: 189.366 ALNY: 32.686 low: -1502.128 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.521 | |
| CapEx To Revenue | -0.01 | |
| CapEx To Depreciation | -0.88 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.3 B | |
| Net Invested Capital | $ 1.3 B | |
| Invested Capital | $ 1.3 B | |
| Net Tangible Assets | $ 233.9 M | |
| Net Working Capital | $ 2.4 B | |
| LIQUIDITY | ||
| Cash Ratio | 1.752 | |
| Current Ratio | 2.541 | |
| Current Ratio QoQ | -9.275 % | |
| Current Ratio YoY | -7.553 % | |
| Current Ratio IPRWA | high: 25.502 mean: 4.45 median: 3.448 ALNY: 2.541 low: 0.046 |
|
| Quick Ratio | 2.493 | |
| Quick Ratio QoQ | -9.219 % | |
| Quick Ratio YoY | -7.215 % | |
| Quick Ratio IPRWA | high: 13.391 mean: 2.767 ALNY: 2.493 median: 2.257 low: 0.043 |
|
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 4.403 | |
| Cost Of Debt | 2.692 % | |
| Interest Coverage Ratio | 6.382 | |
| Interest Coverage Ratio QoQ | 5155.191 % | |
| Interest Coverage Ratio YoY | -395.345 % | |
| Interest Coverage Ratio IPRWA | high: 815.709 mean: 42.498 ALNY: 6.382 median: 1.617 low: -1538.4 |
|
| Operating Cash Flow Ratio | -0.078 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | 70.21 | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 6.256 % | |
| Revenue Growth | 61.438 % | |
| Revenue Growth QoQ | 103.376 % | |
| Revenue Growth YoY | -355.109 % | |
| Revenue Growth IPRWA | high: 301.849 % ALNY: 61.438 % mean: 4.126 % median: 4.118 % low: -259.856 % |
|
| Earnings Growth | -668.627 % | |
| Earnings Growth QoQ | -113.373 % | |
| Earnings Growth YoY | -217.461 % | |
| Earnings Growth IPRWA | high: 162.5 % median: -6.667 % mean: -13.761 % low: -198.545 % ALNY: -668.627 % |
|
| MARGINS | ||
| Gross Margin | 83.975 % | |
| Gross Margin QoQ | 3.008 % | |
| Gross Margin YoY | 1.357 % | |
| Gross Margin IPRWA | high: 105.39 % median: 85.216 % ALNY: 83.975 % mean: 79.508 % low: -35.147 % |
|
| EBIT Margin | 22.687 % | |
| EBIT Margin QoQ | 3489.715 % | |
| EBIT Margin YoY | -252.98 % | |
| EBIT Margin IPRWA | high: 3270.865 % median: 36.648 % ALNY: 22.687 % mean: -124.974 % low: -8139.786 % |
|
| Return On Sales (ROS) | 29.462 % | |
| Return On Sales QoQ | -1506.972 % | |
| Return On Sales YoY | -298.665 % | |
| Return On Sales IPRWA | high: 70.107 % ALNY: 29.462 % median: 26.151 % mean: -193.768 % low: -8613.378 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 313.0 M | |
| Free Cash Flow Yield | 0.539 % | |
| Free Cash Flow Yield QoQ | 89.789 % | |
| Free Cash Flow Yield YoY | 372.807 % | |
| Free Cash Flow Yield IPRWA | high: 30.655 % median: 1.086 % ALNY: 0.539 % mean: 0.311 % low: -51.525 % |
|
| Free Cash Growth | 124.45 % | |
| Free Cash Growth QoQ | -159.39 % | |
| Free Cash Growth YoY | -288.629 % | |
| Free Cash Growth IPRWA | high: 190.123 % ALNY: 124.45 % mean: 22.392 % median: 21.696 % low: -182.653 % |
|
| Free Cash To Net Income | 1.246 | |
| Cash Flow Margin | -9.709 % | |
| Cash Flow To Earnings | -0.483 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.04 | |
| Return On Assets (ROA) | 5.332 % | |
| Return On Assets QoQ | -453.113 % | |
| Return On Assets YoY | -296.318 % | |
| Return On Assets IPRWA | high: 30.5 % ALNY: 5.332 % median: -0.408 % mean: -2.702 % low: -66.968 % |
|
| Return On Capital Employed (ROCE) | 8.597 % | |
| Return On Equity (ROE) | 1.073 | |
| Return On Equity QoQ | -505.887 % | |
| Return On Equity YoY | -131.13 % | |
| Return On Equity IPRWA | ALNY: 1.073 high: 0.948 median: -0.002 mean: -0.005 low: -1.385 |
|
| DuPont ROE | 103.647 % | |
| Return On Invested Capital (ROIC) | 17.569 % | |
| Return On Invested Capital QoQ | 5717.55 % | |
| Return On Invested Capital YoY | 719.832 % | |
| Return On Invested Capital IPRWA | high: 26.519 % ALNY: 17.569 % median: 4.232 % mean: -1.42 % low: -73.241 % |
|